Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients
- 1 August 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (12) , 1675-1677
- https://doi.org/10.1097/01.aids.0000238418.43937.3b
Abstract
We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.Keywords
This publication has 15 references indexed in Scilit:
- Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemiaPublished by Elsevier ,2004
- Cardio- and cerebrovascular events in HIV-infected personsAIDS, 2004
- Lipid Lowering Therapy with Fluvastatin and Pravastatin in Patients with HIV Infection and Antiretroviral Therapy: Comparison of Efficacy and Interaction with IndinavirInfection, 2004
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary HypercholesterolemiaCirculation, 2003
- Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV-1 Infection: Recommendations of an International AIDS Society–USA PanelJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia.Expert Opinion on Drug Safety, 2002
- Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047AIDS, 2002
- Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 2002
- Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and SimvastatinAntimicrobial Agents and Chemotherapy, 2001